Kamada management will host an investment community conference call on Tuesday, August 2, 2016 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Kamada announced the appointment of Naveh Tov, M.D., Ph.D., to the position of Vice President, Clinical Development and Medical Director for Pulmonary Diseases, effective July 1, 2016.
GLASSIA [Alpha-1 Proteinase Inhibitor (Human)] is the only FDA approved alpha-1 antitrypsin (AAT) augmentation treatment that patients can self-infuse at home.
Announced a collaboration to provide early access throughout Europe to Kamada's proprietary, highly-purified, liquid form of Alpha-1 Antitrypsin (AAT) to treat bone marrow transplant patients who develop steroid refractory Graft-Versus-Host Disease (GvHD).
The company announces financial results for the three months ended March 31, 2016.
The company announces that it will release financial results for the first quarter ended March 31, 2016 prior to the open of the U.S. financial markets on Monday, May 9, 2016.
The company announces receipt of two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Chiesi Farmaceutici S.p.A. and Baxalta Incorporated (NYSE: BXLT).
The company announces in the initiation of a Phase 2 clinical trial with its proprietary Alpha-1 Antitrypsin (AAT) for the prevention of lung transplant rejection. The study is being conducted in collaboration with Baxalta Incorporated (NYSE: BXLT), which has distribution rights to the Company's intravenous (IV) AAT for all indications in the U.S., Canada, Australia and New Zealand.
The company announces the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the Company's proprietary, inhaled alpha-1 antitrypsin (AAT) therapy as a treatment for AAT deficiency (AATD). The filing was validated by the EMA.